Syndromes that Mimic an Excess of Mineralocorticoids

High Blood Pressure and Cardiovascular Prevention

Volumn 23, Issue 3, 2016, Pages 231-235

  Sabbadin, Chiara ^a   Armanini, Decio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

11 Hydroxysteroid dehydrogenase type 2; Aldosterone; Apparent mineralocorticoid excess syndrome; Deoxycorticosterone; Hypertension; Licorice; Mineralocorticoid receptor; Pseudohyperaldosteronism

Indexed keywords

11 HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; AMILORIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBENOXOLONE; CONTRACEPTIVE AGENT; CORTICOSTEROID; DEXAMETHASONE; ELECTROLYTE; FLUDROCORTISONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; OXIDOREDUCTASE; PROGESTERONE; RENIN; SODIUM; SODIUM CHANNEL; SODIUM CHLORIDE COTRANSPORTER; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADRENAL GLAND; APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; BLOOD PRESSURE; CHROUSOS SYNDROME; CUSHING SYNDROME; ENZYME DEFECT; EPITHELIUM; FLUID INTAKE; GLYCYRRHIZA; GORDON SYNDROME; GRAPEFRUIT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INFLAMMATION; KIDNEY DISTAL TUBULE; LIDDLE SYNDROME; PRIORITY JOURNAL; PSEUDOHYPERALDOSTERONISM; PSEUDOHYPOALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE; STEROIDOGENESIS; WATER ABSORPTION; BLOOD; DIET; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; PHENOTYPE; RISK FACTOR; UPREGULATION;

ALDOSTERONE; BIOMARKERS; CUSHING SYNDROME; DEXAMETHASONE; DIET; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; LIDDLE SYNDROME; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PHENOTYPE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS; UP-REGULATION;

EID: 84987621415     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-016-0160-5     Document Type: Article

References (20)

1. Armanini D, Strasser T, Weber PC. Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol. 1985;248:E388–90.
2. Bordin L, Donà G, Sabbadin C, Ragazzi E, Andrisani A, Ambrosini G, Brunati AM, Clari G, Armanini D. Human red blood cells alterations in primary aldosteronism. J Clin Endocrinol Metab. 2013;98:2494–501.
3. Armanini D, Calò L, Semplicini A. Pseudohyperaldosteronism: pathogenetic mechanisms. Crit Rev Clin Lab Sci. 2003;40:295–335.
4. Scaroni C, Opocher G, Mantero F. Renin-angiotensin-aldosterone system: a long-term follow-up study in 17 alpha-hydroxylase deficiency syndrome (17OHSD). Clin Exp Hypertens A. 1986;8:773–80.
5. Zhao LQ, Han S, Tian HM. Progress in molecular-genetic studies on congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. World J Pediatr. 2008;4:85–90.
6. Osmond JM, Dorrance AM. 11β-Hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia. Endocrinology. 2009;150:713–9.
7. Calò LA, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P, Martire G, Fiore C, Armanini D. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab. 2004;89:1973–6.
8. Pizzolo F, Friso S, Morandini F, Antoniazzi F, Zaltron C, Udali S, Gandini A, Cavarzere P, Salvagno G, Giorgetti A, Speziali G, Choi SW, Olivieri O. Apparent mineralocorticoid excess by a novel mutation and epigenetic modulation by HSD11B2 promoter methylation. J Clin Endocrinol Metab. 2015;100:E1234–41.
9. + balance and blood pressure. Physiology (Bethesda). 2014;29:16–26.
10. Ferraù F, Korbonits M. Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol. 2015;173:M133–57.
11. Charmandari E, Lino T, Chrousos GP. Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev. 2013;24:67–85.
12. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119–23.
13. Glover M, Ware JS, Henry A, Wolley M, Walsh R, Wain LV, Xu S, Van’t Hoff WG, Tobin MD, Hall IP, Cook S, Gordon RD, Stowasser M, O’Shaughnessy KM. Detection of mutations in KLHL3 and CUL3 in families with FHHt (familial hyperkalaemic hypertension or Gordon’s syndrome). Clin Sci (Lond). 2014;126:721–6.
14. Armanini D, Lewicka S, Pratesi C, Scali M, Zennaro MC, Zovato S, Gottardo C, Simoncini M, Spigariol A, Zampollo V. Further studies on the mechanism of the mineralocorticoid action of licorice in humans. J Endocrinol Invest. 1996;19:624–9.
15. Scali M, Pratesi C, Zennaro MC, Zampollo V, Armanini D. Pseudohyperaldosteronism from liquorice-containing laxatives. J Endocrinol Invest. 1990;13:847–8.
16. Palermo M, Armanini D, Delitala G. Grapefruit juice inhibits 11beta-hydroxysteroid dehydrogenase in vivo, in man. Clin Endocrinol (Oxf). 2003;59:143–4.
17. Armanini D, Karbowiak I, Krozowski Z, Funder JW, Adam WR. The mechanism of mineralocorticoid action of carbenoxolone. Endocrinology. 1982;111:1683–6.
18. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012;44:170–6.
19. Armanini D, Fiore C, Pellati D. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension. 2007;50:e69–70.
20. Armanini D, Fiore C. Some considerations about evolution of idiopathic primary aldosteronism. J Endocrinol Invest. 2009;32:623–5.